Global Artificial Intelligence In Medicine Market to Reach 15,000.00 Million by 2026 – Facts & Factors
The MarketWatch News Department was not involved in the creation of this content.
New York, NY, Nov 17, 2020 (GLOBE NEWSWIRE via COMTEX) —
New York, NY, Nov. 17, 2020 (GLOBE NEWSWIRE) — Facts and Factors have published a new research report titled “Artificial Intelligence in Medicine Market By Component (Hardware, Software, Service), By Application (Robot Assisted Surgery, Virtual Nursing Assistants, Administrative Workflow Assistance, Fraud Detection, Connected Machines, Clinical Trial, Preliminary Diagnosis, Others), By End-User (Healthcare Provider, Pharmaceutical & Biotechnology Company, Patient, Payer, Others), and By Technology (Querying Method, Natural Language Processing, Context Aware Processing, Speech Recognition, Decision Management, Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020-2026”.
According to the research study, the global Artificial Intelligence in Medicine Market was estimated at USD 800 million in 2019 and is expected to reach USD 15,000 million by 2026. The global Artificial Intelligence in Medicine Market is expected to grow at a compound annual growth rate (CAGR) of 49% from 2020 to 2027.
The Global Artificial Intelligence In Medicine Market Is Powered By The Need To Minimise Healthcare Costs, The Importance Of Big Data In Healthcare, The Increasing Acceptance Of Precision Medicine, And The Decreasing Hardware Costs.
Artificial intelligence in medicine is likely to transform the doctor’s character expressively and revolutionize the preparation of medicine. Across has transformed medical specialties and addresses the benefits and challenges of this new technology. Doctors, particularly those in management positions, are developing in health the need to be receptive to AI rapidly, so they remain ready to make the necessary change for their acceptance into the health system. In the study of different medical conditions, the AI is useful as individuals, and in certain circumstances, extra efficient. In the investigation of complicated medical evidence, AI in medicine is the use of compound algorithms and machines to imitate hominid reasoning. AI is, in reality, the capacity of computer systems to approximate decisions without human feedback.
Browse through 34 Tables & 97 Figures spread over 180+ Pages and in-depth TOC on “Global Artificial Intelligence in Medicine Market Size & Share 2020 Analysis and Industry Forecast to 2027”.
Request Free Sample Report of Global Artificial Intelligence in Medicine Market @ https://www.fnfresearch.com/sample/artificial-intelligence-in-medicine-market-by-component-hardware-830
In order to recognize errors in existing scenarios and provide potential options in complicated situations, the increasingly growing use of cloud computing techniques has encouraged the adoption of artificial intelligence solutions for mining vast volumes of data. Many participants in the medical sector have promoted the use of AI technologies as it can theoretically boost the service offered by many. The key functions that involve the highest AI integration in the industry are access to documentation, the processing of patient-related symptoms, and the communication of subsequent therapies. With advanced cognitive technologies, IBM Watson is driving the transformation in the medical sector to dynamically understand, reason, and learn and commit to ensuring timely quality and informed decision-making. It has been projected that the healthcare sector
Around 19 million NHS dental appointments have been missed due to coronavirus guidelines restricting services, dentists have warned.
In a letter to Matt Hancock, the Health Secretary, the British Dental Association (BDA) has called on the Government to invest in practices to help them increase their capacity and provide vital care.
Nearly three quarters of practices are operating at half their pre-pandemic capacity, according to a survey carried out by the BDA, with nearly two thirds (63 per cent) reporting that they are focusing on emergency cases over routine dentistry.
The “major obstacle” to increasing capacity is “fallow time” – the mandated time needed between patients to minimise risks of coronavirus transmission – dentists say.
And despite new regulations allowing dentists to cut this wait time down from 60 minutes following an Aerosol Generating Procedure (APG) to potentially as low as 15 minutes, 57 per cent said they lack the funds to invest in the equipment required to do so.
As a result, tens of millions of patients are missing out on treatment, according to the BDA.
Data obtained through freedom of information requests show there were around 14.5 million fewer treatments delivered by NHS dentists in England between April and August 2020 compared to the same period last year – where monthly delivery was around 3.3million on average.
According to the BDA activity has not exceeded a third of normal levels for September and October, bringing the number of missed courses to an estimated 19 million.
“Covid-19 restrictions on patient throughput, set by government, are placing significant limits on the number of patients we can treat for the foreseeable future. Your support could help bring tens of millions of patients back through our doors to get the care they need,” the letter to Mr Hancock states.
Eddie Crouch, BDA Chair, said coronavirus restrictions have left dentists “firefighting with huge backlogs”.
“We now face a Catch-22. New rules could bring back a dose of normality, but come with a multi-million-pound bill for new kit that practices simply cannot afford,” he said.
“On paper we have a chance to restore services to millions, but without support from Government it won’t translate into better access.”
Albert Einstein College of Medicine researchers receive $5 million NIH grant to study HIV and HPV cancers in Africa
November 13, 2020–(BRONX, NY)–A team of scientists from Albert Einstein College of Medicine has received a five-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate HIV- and human papillomavirus (HPV)-related cancers in Africa.
The HIV-Associated HPV-related Malignancies Research Center will build on Einstein-led efforts that have already improved research, clinical, and laboratory capacity in Rwanda. More than 200,000 people in Rwanda have HIV, and women have a higher burden of the disease, according to the Centers for Disease Control and Prevention. Additionally, cervical cancer, which is caused by HPV and which women with HIV are at greater risk of developing, is one of the two most common malignancies among Rwandan women. HPV is also linked to the development of anal, penile, and head and neck cancers.
The grant will enable Einstein researchers and their partners to expand the Rwandan programs and launch similar initiatives in the Democratic Republic of the Congo (DRC). These efforts will help improve health outcomes for millions of Africans living with HIV whose incidence of diseases, including cancer, is increasing as they live longer due to effective HIV therapies.
“We aim to develop a cadre of Rwandan and DRC scientific leaders and build the necessary physical and administrative infrastructure to launch and sustain this project,” said Kathryn Anastos, M.D., lead investigator on the grant and a member of the Albert Einstein Cancer Center, which has supported previous work in Rwanda, including efforts to bring Rwandans to the United States to train.
“Our new NIH-funded center in Africa will serve as a national and regional resource hub for research, training, and career development for those studying the epidemiology, pathogenesis, prevention, and treatment of HPV-associated malignancies in people living with HIV,” added Dr. Anastos, who is professor of medicine, of epidemiology & population health, and of obstetrics & gynecology and women’s health at Einstein and an internist at Montefiore Health System.
Dr. Anastos is recognized internationally for her clinical and investigative work in HIV-infected women, and she has long been involved in leading complex multi-faceted research projects in the United States and Rwanda. Other principal investigators on the grant are Adebola Adedimeji, Ph.D., M.B.A., research associate professor of epidemiology & population heath, and Marcel Yotebieng, M.D., Ph.D., M.P.H., associate professor of medicine, both from Einstein, and Leon Mutesa, M.D., Ph.D., professor of human genetics and director of the Center for Human Genetics at the College of Medicine and Health Sciences-University of Rwanda. The Einstein team includes more than a dozen other faculty members from a range of departments and specialties, including several from the Albert Einstein Cancer Center. They will partner with three African institutions: University of Rwanda, Rwanda Military Hospital, and Université Protestante au Congo.
The grant will support two research projects. One is the first population-based assessment of the effectiveness of HPV vaccination in women living with HIV. The study also will compare the HPV
If you peek inside a Planet Fitness (NYSE: PLNT) gym location these days, things look busy. Granted, it might not be as busy as it once was, but members are nonetheless exercising despite the ongoing COVID-19 pandemic. Management says that its usage rates (how many people are actually present in the building) are currently 67% to 74% of what they were last year at this time.
The usage rate appears to be trending in the right direction. But it doesn’t tell the whole story for Planet Fitness, and the next stat should give investors pause. Since July, the company has lost over 1 million members.
The mass exodus
Gyms weren’t considered an essential business when government decision-makers were trying to determine what could stay open shortly after the COVID-19 pandemic began. As a result, all 2,000 Planet Fitness locations were closed at some point in 2020. However, somewhat surprisingly, the company lost relatively few members while gym locations were closed.
Planet Fitness charges a monthly membership fee, but the fee was waived while gyms were closed. This gave members very little incentive to cancel their memberships early on. However, as gyms started reopening, the company started to bill people once again. And once this happened, there was a mass exodus.
In the conference call to discuss third-quarter results, Planet Fitness management said it noticed a lot of losses during the second-month billing. This seems to imply members were charged for the first month after their local gym reopened, perhaps unaware it had started back up. But they made sure to cancel before having to pay the second bill.
Putting it in context
Membership for Planet Fitness peaked in the first quarter of 2020 at 15.5 million. This was an incredible jump from the prior quarter when it had 14.4 million members. But the timing of this jump makes sense. With the dawn of a new year, many people resolve to exercise more frequently.
This 1.1 million-member jump came on the heels of a hot 2019. In 2019, Planet Fitness added a whopping 1.9 million members. Totaling it up, from the end of 2018 to the start of the COVID-19 pandemic in the U.S., the company had added 3 million members — up an impressive 24% over just five fiscal quarters. Then the coronavirus derailed the train.
As of October, Planet Fitness was down to 14 million members. The last time the company had just 14 million members was in the second quarter of 2019. Back then, there were 1,859 locations. Now there are 2,086. So, not only has membership fallen, but members per location have plummeted dramatically.
Why it matters
Planet Fitness may have merely lost low-commitment members. The company expressly targets
MISGAV, Israel, Nov. 10, 2020 /PRNewswire/ — Limaca Medical, (“Limaca”) a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel– and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced it has closed $1.25 million of a $1.5 million round to complete first-in-human (“FIH”) procedures, post-market clinical studies, and obtain regulatory approvals.
Limaca has raised $1.25 million from Trendlines, Agriline (ultimately owned by a trust of which Vincent Tchenguiz is a discretionary beneficiary), Limaca Chairman and medical device industry veteran Carl Rickenbaugh, and a private investor.
The Precision™ biopsy device developed by Limaca deploys an automated revolving needle to acquire high-quality core tissue for histopathology and advanced genetic profiling. The Precision device makes it possible to acquire biopsy tissue samples at ten times greater procedural efficiency with less trauma than today’s endoscopic standard of care for greater diagnostic accuracy and patient-specific treatment to achieve better clinical outcomes.
Limaca’s CEO Assaf Klein commented, “We designed Precision to improve upon endoscopic biopsies and make a substantial leap forward in this critical diagnostic procedure to advance precision treatment and achieve superior outcomes for cancer patients.”
To date, 10 patients have been enrolled in Limaca’s FIH study at the Rambam Health Care Campus in Israel. The FIH study compares Limaca’s Precision to standard of care EUS biopsy devices. Results have demonstrated excellent ease of use, safety, and improved sample capture. Iyad Khamaysi, MD, Director, Invasive Endoscopy Unit, Rambam Health Care, and one of Limaca’s founders, states, “Precision exceeded all clinical expectations for endoscopic biopsy while demonstrating clear safety in our cases.”
Limaca’s initial market is biopsy sampling for pancreatic cancer, an $850 million opportunity. Current methods used for sampling of this deadly cancer are outdated and provide poor tissue samples, frequently requiring a second biopsy procedure to acquire more tissue for diagnostic testing. Additional markets for Precision, which are estimated at over $400 million, address biopsy sampling for the diagnosis of lung cancer, liver biopsy, lymphoma, and other cancers where endoscopic biopsy is feasible and subcutaneous tissue sampling is difficult.
Carl Rickenbaugh, Limaca’s Chairman, comments “The medical provider and payor markets respond to superior devices when they demonstrate strong clinical relevancy. We built Limaca to address the need for a more efficient endoscopic procedure for the provider, and for the cancer patient and payor, greater certainty to gain sufficient sample quality and quantity needed for pathology as well as more stringent genetic testing requirements.”
Assaf Klein, CEO Limaca Medical
View original content to download multimedia:https://www.prnewswire.com/news-releases/limaca-medical-raises-1-25-million-to-enhance-precision-medicine-through-improved-biopsies-301169885.html
SOURCE Limaca Medical
Asia Pacific cannabis market is expected to reach US$ 22,870.6 million by 2027 from US$ 2,318.6 million in 2019
The market is anticipated to grow with a CAGR of 28. 6% from 2020 to 2027. The growth of the Asia Pacific cannabis market is attributed to increasing research on medical cannabis and rising cannabis industry in Southeast Asia.
New York, Nov. 03, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Cannabis Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product Type ; Application ; Compound, and Country” – https://www.reportlinker.com/p05978820/?utm_source=GNW
However, restriction on the use of cannabis in the region is likely to hinder the market growth during the forecast period.
In recent years, the liberation for the use of cannabis in the medical industry has created various growth opportunities in Southeast Asian countries.Growing legal jurisdictions have enabled the progress of research activities in countries, such as South Korea, Australia, and New Zealand.
Also, various international companies have shown interest in effective market strategies.The companies have strategically enhanced their operational activities by partnering with local players.
For instance, a Canadian market player, Canopy Growth, has expanded its production in South Korea and Thailand.Similarly, MYM Nutraceuticals has expanded its business through its subsidiary MYM Australia.
Such expansions by the companies are expected to drive the cannabis market in the region.
Thailand is among the largest producers of cannabis.In late 2018, it became a cannabis production hub for legalized medical cannabis.
In addition, in December 2018, the military of Thailand voted to legalize medical cannabis use and in February 2019, Thailand legalized medical use of cannabis.Similarly, in January 2019, the Philippine House of Representatives approved the legalization of cannabis in the Philippines.
It has also created a Medical Cannabis Compassionate Center to initiate the creation of a legal cannabis industry.In March 2019, South Korea legalized medical use of cannabis.
Moreover, in March 2019, Japan approved the cannabis compound Epidiolex for clinical trials. Thus, such approvals for cannabis-based products are likely to drive market for cannabis in the Asia Pacific region.
On the other hand, the COVID-19 outbreak is growing in an unexpected way.For instance, according to an article published in May 2020, saying, “The study mentions how they have identified a minimum of 13 cannabis plants that are high in CBD that can affect the ACE2 pathways that the coronavirus uses to get inside one’s body”.
Therefore, it is expected to increase the use of medical cannabis to treat symptoms of COVID-19.
Based on product type, the Asia Pacific cannabis market is segmented into flower, concentrates, and others.In 2019, the flower segment held the largest market share of the cannabis market.
However, the concentrates segment is expected to witness the highest CAGR in the next few years.
In terms of application, the Asia Pacific cannabis market is segmented into medical and recreational.In 2019, the medical segment held larger share of the market.
However, the recreational segment is anticipated to witness fastest growth during the forecast period.
Based on compound, the Asia Pacific cannabis market is segmented into tetrahydrocannabinol (THC)-dominant, cannabidiol (CBD)-dominant, and balanced THC
Russell Wilson spends $1 million on full-time trainers and chefs every year.
The 31-year-old quarterback has invested a lot of money into keeping his body healthy so he can continue playing American football until he reaches 45 years old as most players retire at 35 years old.
Speaking on ‘The Bill Simmons Podcast’, he admitted: “I probably spend $1 million if not more, a year, just on recovery.”
Russell – who wed Ciara in 2016 – went into detail about how he spends his money with the help of a “performance” team who help to keep his body in check.
He explained: “I have a whole performance team. I have a whole group. I got a full-time trainer that travels with me everywhere, works with Ciara too. I have a full-time PT, I have a full-time mobile person that’s working on me and making sure that I’m moving the right way and everything else. I have a full-time massage person and two chefs.
“I’m trying to play until I’m 45 at least. So for me, my mentality is that I’m gonna leave it all on the field and do everything I can to take care of myself. And that’s such a critical thing because if I feel good, I’m gonna play good, and I think that’s why I’ve been able to be out in the field every time.”
However, it’s not all work for the Seattle Seahawks player as he does take one or two days off a year to spend the holidays with his family.
He added: “The reality is Christmas – depending on the circumstances, but usually I do because we usually have a game around then – and Thanksgiving. I’m between 363 and 365 amount of work that we do every day, something around the work I do.”
The global defibrillator market is predicted to grow from $9,621.2 million to $20,281.6 million from 2019 to 2030
Defibrillator Market Research Report: By Type (Implantable Cardioverter Defibrillators, External Defibrillators), Patient Type (Adult, Pediatric), Distribution Channel (Direct, Indirect), End User (Hospitals, Clinics, & Cardiac Centers, Pre-Hospital Care Settings, Public Access Settings, Home Care Settings) – Global Industry Analysis and Growth Forecast to 2030
New York, Nov. 03, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Defibrillator Market Research Report: By Type, Patient Type, Distribution Channel, End User – Global Industry Analysis and Growth Forecast to 2030” – https://www.reportlinker.com/p05982505/?utm_source=GNW
There has been a sharp rise in the prevalence of cardiac diseases all over the world over the last few years. This is because of the rising consumption of fast foods and high-calorie food times, increasing adoption of sedentary lifestyles, rising incidence of smoking, and soaring obesity levels around the world. Moreover, the increasing stress levels being caused due to the rising peer pressure, growing financial responsibilities, and long working hours, especially in the developing countries, are further augmenting the incidence of various heart-related ailments and cardiovascular diseases (CVDs), which is, in turn, boosting the global demand for defibrillators.
As per the findings of the World Health Organization (WHO), “CVDs are the major cause of death, globally. In 2016, approximately 17.9 million people died due to CVDs, representing 31% of the total deaths, globally. Of these deaths, 85% were due to heart attack and stroke.” Similarly, as per the 2017 report Heart Disease and Stroke Statistics published by the American Heart Association (AHA), in the U.S., one out every three people die because of a CVD every year, which equals to, the deaths of nearly 800,000 people every year.
The Nature Reviews Cardiology journal published an article titled ‘Causes and Prevention of Sudden Cardiac Death in the Elderly’ in 2013, which stated that sudden cardiac arrest (SCA) was one of the major causes of death in geriatric people in the U.S. This was because of the high incidence of CHDs, congestive heart failure (CHF), and systolic dysfunction in the elderly people. Due to these factors, the sales of defibrillators are rising rapidly throughout the world. As a result, the revenue of the global defibrillator market is predicted to grow from $9,621.2 million to $20,281.6 million from 2019 to 2030.
Hence, it can be said without any hesitation that the sales of defibrillators will surge all over the world in the upcoming years, because of the growing prevalence of chronic and cardiovascular diseases (CVDs) and the presence of a soaring geriatric population in many countries around the world.
Read the full report: https://www.reportlinker.com/p05982505/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
By Radovan Stoklasa
TRENCIN, Slovakia (Reuters) – Over a million Slovaks took a coronavirus swab on Saturday as the country launched a huge logistical operation to test most of its population over the weekend to reverse a rise in the pandemic.
Authorities say the ambitious plan to test most citizens aged over 10 among Slovakia’s 5.5 million people is the first of its kind in a country of its size.
It is being watched by other nations looking for ways to slow the virus spread and avoid overwhelming their health systems.
More than 40,000 medics and support teams of soldiers, police, administrative workers and volunteers staffed around 5,000 sites to administer the antigen swab tests.
As of noon (1100 GMT), 828,518 people had been tested and 7,947 were positive, Defence Minister Jaroslav Nad told a news conference.
“We have clearly got to over 1 million (as of 1500 GMT) – people’s interest continues,” Nad said, adding that over 3 million people may be tested over the course of the weekend.
Prime Minister Igor Matovic has said he hoped the plan would identify and quarantine enough infected people to avert a strict lockdown for everyone.
The testing was free and voluntary, but the government will impose lockdowns on people who do not participate, including a ban on going to work.
Martin Janosik, a 44-year-old entrepreneur, said he had taken part so his son would be allowed to attend school.
“I did not have much of a choice, but I did not think much about it,” he told Reuters at a testing centre in Trencin, a city north of the capital Bratislava.
“It is also good for me and for my company, if I am healthy I can be there and take people around.”
Slovak media reported up to four-hour queues but waiting times were getting shorter in the afternoon.
Some of the sites at schools, sports grounds, theatres, car parks and companies opened late on Saturday amid lack of staff or material, but Nad said 99% of sites were operational by early afternoon.
The antigen test gives results in just 15-30 minutes but is less accurate than the molecular PCR method.
Opponents of the scheme have pointed to a Czech study that found antigen tests identified only around 70% of infections detected by PCR tests, but the government has insisted that even at that level of accuracy the exercise is worth it.
Critics also question whether requiring people to show a negative test in order to move around freely complies with data protection rules.
A second round of testing is planned for a week’s time.
Slovakia reported 2,573 COVID-19 cases on Saturday through PCR testing, bringing the total to 57,664, with 219 deaths.
(Reporting by Radovan Stoklasa; Writing by Jan Lopatka; editing by John Stonestreet and Ros Russell)
Geneva, Switzerland, November 2, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that the research term of the agreement signed with Indivior PLC (LON: INDV) in January 2018 has been extended until June 30, 2021. The collaboration with Indivior covers the discovery of novel oral gamma-aminobutyric acid receptor subtype B (GABAB) positive allosteric modulator (PAM) compounds as potential therapies for multiple disease areas. As part of the amended agreement, Indivior has agreed to pay Addex $2.8 million in research funding and expand the therapeutic areas where Addex has exclusivity to develop retained compounds.
“The extension of our research collaboration and the additional funding from Indivior is a clear recognition of the potential of our allosteric modulator discovery platform and the significant achievements of our drug discovery team,” said Tim Dyer, CEO of Addex. “Indivior is a world leader in the development of addiction medication and strongly committed to GABAB PAM as a potential treatment for addiction including alcohol use disorder.”
“Although 200 health conditions have been linked to harmful alcohol use,1 there are few pharmacotherapies for alcohol use disorder (AUD) – their efﬁcacy and uptake in clinical practice are limited, and patient acceptance is minimal. We are, therefore, very pleased to expand our partnership with Addex Therapeutics to discover and profile new potent and selective GABAB PAMs and provide a new class of medications that has the potential to achieve therapeutic benefits in patients suffering from AUD,” said Christian Heidbreder, Chief Scientific Officer of Indivior.
“Due to the extensive validation of GABAB activation with baclofen, we believe a novel, orally available GABAB PAM could provide significant benefits to patients in many therapeutics areas,” said Jean-Philippe Rocher, Co-Head of Discovery. “We have advanced multiple novel chemical series’ to late stages of lead optimization and we look forward to rapidly delivering first-in-class compounds for Indivior to advance into clinical development.”
Under the terms of the original agreement signed with Indivior in January 2018, Addex received a $5 million upfront payment and has since received $5.6 million research funding. Addex is eligible to receive up to $330 million of development, regulatory and commercialization milestones as well as tiered royalties up to teen double-digit. In addition, Addex has the right to retain certain compounds and pursue their development for reserved indications outside addiction, including for the treatment of Charcot-Marie-Tooth type 1a (CMT1A) neuropathy, a rare inherited disorder that affects peripheral nerves. Addex has discovered novel GABAB PAMs and has made significant progress in optimization of potential drug candidates. Addex expects to enter clinical candidate selection phase by end of 2020 and deliver drug candidates for IND enabling studies by the end of 2021 for both Indivior and for its in-house CMT1A program.
About GABAB Activation with PAM
Activation of the GABAB receptor, a Family C class of GPCR, is clinically and commercially validated by the generic GABAB